Get the Stockscreener App
27.97
1.19%
0.33
After Hours:
28.40
0.43
+1.54%
Rapport Therapeutics Inc stock is traded at $27.97, with a volume of 307.93K.
It is up +1.19% in the last 24 hours and up +3.59% over the past month.
Rapport Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovery and development of transformational small-molecule medicines for patients suffering from central nervous system disorders. Its foundational science has elucidated the complexities of neuronal receptor biology and enables the company to map and target certain neuronal receptor complexes. Neuronal receptors are complex assemblies of proteins, comprising receptor principal subunits and their receptor-associated proteins (RAPs), the latter of which play crucial roles in regulating receptor expression and function.
See More
Previous Close:
$27.64
Open:
$27.81
24h Volume:
307.93K
Relative Volume:
0.84
Market Cap:
$1.33B
Revenue:
-
Net Income/Loss:
-
P/E Ratio:
-
EPS:
-
Net Cash Flow:
-
1W Performance:
+9.47%
1M Performance:
+3.59%
6M Performance:
+79.99%
1Y Performance:
+73.40%
1-Day Range:
$26.70
$28.56
1-Week Range:
$25.78
$28.99
52-Week Range:
$7.13
$42.27
Rapport Therapeutics Inc Stock (RAPP) Company Profile
Name
Rapport Therapeutics Inc
Sector
Industry
Phone
857-321-8020
Address
99 HIGH STREET, BOSTON
Compare RAPP vs VRTX, REGN, ARGX, ALNY, ONC
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
RAPP
Rapport Therapeutics Inc
|
27.97 | 1.32B | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
465.02 | 117.03B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.65 | 82.35B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
833.54 | 51.64B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
308.48 | 42.58B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ONC
Beone Medicines Ltd Adr
|
346.42 | 38.87B | 4.98B | 69.60M | 525.67M | 0.5198 |
Rapport Therapeutics Inc Stock (RAPP) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Feb-02-26 | Initiated | Wells Fargo | Overweight |
| Nov-19-25 | Initiated | BTIG Research | Buy |
| Sep-16-25 | Initiated | Truist | Buy |
| Aug-06-25 | Initiated | H.C. Wainwright | Buy |
| Apr-08-25 | Initiated | Citizens JMP | Mkt Outperform |
| Jul-02-24 | Initiated | Jefferies | Buy |
| Jul-02-24 | Initiated | Stifel | Buy |
| Jul-02-24 | Initiated | TD Cowen | Buy |
View All
Rapport Therapeutics Inc Stock (RAPP) Latest News
Understanding Momentum Shifts in (RAPP) - Stock Traders Daily
RSI Check: What hedge funds are buying Rapport Therapeutics IncM&A Rumor & Free High Accuracy Swing Entry Alerts - baoquankhu1.vn
A Look At Rapport Therapeutics (RAPP) Valuation After Fresh Overweight Rating From Wells Fargo - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Stock Rating Lowered by Wall Street Zen - Defense World
Rapport Therapeutics Completes Key Phase 2a Epilepsy Study for RAP-219: What Investors Should Watch Next - TipRanks
Rapport Therapeutics (NASDAQ:RAPP) Now Covered by Analysts at Wells Fargo & Company - Defense World
Wells Fargo Initiates Coverage of Rapport Therapeutics (RAPP) with Overweight Recommendation - Nasdaq
Rapport Therapeutics (RAPP): Analyst Initiates Coverage with Ove - GuruFocus
Wells Fargo Initiates Coverage on Rapport Therapeutics With Overweight Rating, $43 Price Target - marketscreener.com
Wells Fargo & Company Begins Coverage on Rapport Therapeutics (NASDAQ:RAPP) - MarketBeat
Aug Final Week: What are Rapport Therapeutics Inc.’s technical support levels2025 Market WrapUp & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Whale Trades: What is the dividend yield of PMGC Holdings IncWeekly Trading Summary & Fast Gain Swing Alerts - baoquankhu1.vn
Aug Breakouts: Why is Rapport Therapeutics Inc stock going upStock Surge & Accurate Intraday Trading Signals - baoquankhu1.vn
Activity Recap: What hedge funds are buying Rapport Therapeutics IncJuly 2025 PreEarnings & Free Long-Term Investment Growth Plans - baoquankhu1.vn
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: Promising Biotech with Nearly 95% Upside Potential - DirectorsTalk Interviews
Will Rapport Therapeutics Inc. stock gain from strong economyMarket Trend Review & Verified Stock Trade Ideas - mfd.ru
Should I buy Rapport Therapeutics Inc. stock nowCEO Change & Intraday High Probability Setup Alerts - mfd.ru
Is Rapport Therapeutics Inc. undervalued by DCF analysis2025 Fundamental Recap & Intraday High Probability Setup Alerts - mfd.ru
Layoff Watch: Is Rapport Therapeutics Inc gaining market shareQuarterly Portfolio Summary & Free Community Supported Trade Ideas - baoquankhu1.vn
Avoiding Lag: Real-Time Signals in (RAPP) Movement - Stock Traders Daily
Retail Surge: Is Rapport Therapeutics Inc gaining market shareWeekly Stock Summary & Expert Approved Trade Ideas - baoquankhu1.vn
Rapport Therapeutics (NASDAQ:RAPP) Upgraded to Hold at Wall Street Zen - MarketBeat
JonesTrading Maintains Rapport Therapeutics(RAPP.US) With Buy Rating, Maintains Target Price $50 - 富途牛牛
Rapport Therapeutics, Inc. (RAPP): Investor Outlook With An 87% Potential Upside - DirectorsTalk Interviews
Rapport Therapeutics CEO Ceesay sells $285k in shares By Investing.com - Investing.com Australia
Abraham Ceesay Sells 5,833 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - MarketBeat
Rapport Therapeutics CEO Ceesay sells $285k in shares - Investing.com
Short Interest in Rapport Therapeutics, Inc. (NASDAQ:RAPP) Expands By 20.7% - Defense World
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Short Interest Up 20.7% in December - MarketBeat
Rapport Therapeutics, Inc. (NASDAQ:RAPP) Given Average Rating of "Moderate Buy" by Analysts - MarketBeat
David Bredt Sells 8,500 Shares of Rapport Therapeutics (NASDAQ:RAPP) Stock - Defense World
Rapport Therapeutics (RAPP) Is Down 7.4% After Advancing RAP-219 Toward Phase 3 In Epilepsy - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Downgraded by Wall Street Zen to "Sell" - MarketBeat
Discipline and Rules-Based Execution in RAPP Response - Stock Traders Daily
Insider Sell: David Bredt Sells 8,500 Shares of Rapport Therapeu - GuruFocus
Rapport Therapeutics (NASDAQ:RAPP) Insider David Bredt Sells 8,500 Shares - MarketBeat
Rapport Therapeutics, Inc. (RAPP) Stock Analysis: A Biotech With 94.53% Potential Upside - DirectorsTalk Interviews
Rapport Reveals Pricing for Public Common Stock Offering - Intellectia AI
A Look At Rapport Therapeutics (RAPP) Valuation After FDA Clears Phase 3 Trial For RAP-219 - Sahm
Rapport Therapeutics (NASDAQ:RAPP) Trading Down 6.9%Time to Sell? - MarketBeat
Rapport Therapeutics: Diversified Neurology Pipeline and Accelerated RAP-219 Development Underpin Buy Rating - TipRanks
FDA Phase 3 Green Light for RAP-219 Might Change The Case For Investing In Rapport Therapeutics (RAPP) - Sahm
Will Rapport Therapeutics Inc. stock outperform growth indexesJuly 2025 Sector Moves & Safe Capital Growth Tips - Улправда
Rapport Therapeutics, Inc. (RAPP): Investor Outlook with a Promising 84.56% Potential Upside - DirectorsTalk Interviews
Is Rapport Therapeutics Inc. stock a smart buy before Fed meeting2025 Sector Review & Free Expert Approved Momentum Trade Ideas - ulpravda.ru
Can Rapport Therapeutics Inc. stock resist market sell offsQuarterly Portfolio Review & Risk Managed Investment Entry Signals - ulpravda.ru
Form 8-KCurrent report - ADVFN
Rapport Therapeutics (RAPP) Refocuses Neurology Pipeline After RAP-219 Phase 3 Greenlight – What’s the R&D Tradeoff? - Yahoo Finance
A Quick Look at Today's Ratings for Rapport Therapeutics(RAPP.US), With a Forecast Between $40 to $56 - 富途牛牛
Rapport Therapeutics: Accelerated RAP-219 Epilepsy Path to Phase 3 and Strategic Pipeline Refocus Support Buy Rating - TipRanks
Citizens reiterates Market Outperform rating on Rapport Therapeutics stock By Investing.com - Investing.com Canada
Rapport Therapeutics Inc Stock (RAPP) Financials Data
There is no financial data for Rapport Therapeutics Inc (RAPP). Check out other stocks for more information.
Revenue
Net Income
Cash Flow
EPS
1.24%
0.19%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):